Holen Sie sich die Stockscreener-App
5.16
1.34%
-0.07
Handel nachbörslich:
5.16
Schlusskurs vom Vortag:
$5.23
Offen:
$5.26
24-Stunden-Volumen:
164.50K
Relative Volume:
0.78
Marktkapitalisierung:
$291.80M
Einnahmen:
$34.16M
Nettoeinkommen (Verlust:
$-98.43M
KGV:
-2.2051
EPS:
-2.34
Netto-Cashflow:
$-119.33M
1W Leistung:
-0.58%
1M Leistung:
+18.08%
6M Leistung:
-6.35%
1J Leistung:
+10.97%
1-Tages-Spanne:
$5.04
$5.30
1-Wochen-Bereich:
$4.64
$5.37
52-Wochen-Spanne:
$2.9448
$6.7899
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Vergleichen Sie FHTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
5.16 | 295.76M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | BTIG Research | Buy |
| 2025-11-07 | Eingeleitet | Guggenheim | Buy |
| 2025-09-17 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-28 | Eingeleitet | BofA Securities | Buy |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-17 | Eingeleitet | Cowen | Outperform |
| 2020-11-17 | Eingeleitet | Goldman | Buy |
| 2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
Foghorn Therapeutics Inc. Secures $50 Million in Equity Financing to Advance Oncology Pipeline and Strengthen Balance Sheet - Quiver Quantitative
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 - Yahoo Finance
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic ... - Bluefield Daily Telegraph
Will Foghorn Therapeutics Inc. stock benefit from green energy trends - ulpravda.ru
Can Foghorn Therapeutics Inc. stock sustain free cash flow growthWeekly Investment Report & High Accuracy Trade Signal Alerts - ulpravda.ru
Can Foghorn Therapeutics Inc. stock reach $100 price targetEarnings Beat Highlights & Swing Trade Smarter With Data Insights - bollywoodhelpline.com
Why Foghorn Therapeutics Inc. stock is recommended by analystsRisk-Reward Ratio Analysis & Small Budget Big Profits - ulpravda.ru
Will Foghorn Therapeutics Inc. stock continue upward momentumBull Market Opportunities & Outstanding Wealth Building - ulpravda.ru
Is Foghorn Therapeutics Inc. stock a bargain at current levels2026 world cup usa national team group stage top scorers possession football odds analysis expert opinion - ulpravda.ru
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected - simplywall.st
Is Foghorn Therapeutics Inc. stock resilient to inflation2025 Support & Resistance & Real-Time Chart Breakout Alerts - Улправда
What momentum indicators show for Foghorn Therapeutics Inc. stockBuy Signal & Weekly Momentum Stock Picks - Улправда
BTIG Research Begins Coverage on Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to "Buy" - MarketBeat
Is Foghorn Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Decliners & AI Forecast Swing Trade Picks - bolumsonucanavari.com
How Foghorn Therapeutics Inc. stock performs after earningsJuly 2025 Drop Watch & Reliable Breakout Stock Forecasts - Улправда
Foghorn Therapeutics (NASDAQ:FHTX) Earns Buy Rating from Analysts at BTIG Research - MarketBeat
Will Foghorn Therapeutics Inc. stock deliver better than expected guidanceWeekly Stock Recap & Proven Capital Preservation Tips - Улправда
Here's Why We're Watching Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Situation - Sahm
BTIG Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation - Nasdaq
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment - Yahoo Finance
BTIG Research Initiates Coverage on Foghorn Therapeutics With Buy Rating, $11 Price Target - MarketScreener
BTIG Initiates Coverage on FHTX with a Buy Rating and $11.00 Pri - GuruFocus
Support Test: What momentum indicators show for Foghorn Therapeutics Inc. stockPortfolio Return Report & Low Risk Investment Opportunities - Улправда
BTIG initiates Foghorn Therapeutics stock with Buy rating on cancer pipeline - Investing.com Canada
Foghorn Therapeutics (NASDAQ:FHTX) vs. Arcadia Biosciences (NASDAQ:RKDA) Head to Head Analysis - Defense World
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast - Defense World
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
Analyst Confidence Rises for Foghorn Therapeutics Following Leadership and Pipeline Updates - AD HOC NEWS
Foghorn Therapeutics (NASDAQ:FHTX) Stock Rating Lowered by Wall Street Zen - Defense World
Is Foghorn Therapeutics Inc. stock attractive for hedge fundsJobs Report & AI Driven Stock Reports - Newser
Foghorn Therapeutics Appoints Interim CFO Jeff Sacher - The Globe and Mail
Stifel Initiates Coverage of Foghorn Therapeutics (FHTX) with Buy Recommendation - Nasdaq
Stifel Initiates Coverage on FHTX with a 'Buy' Rating | FHTX Sto - GuruFocus
Foghorn Therapeutics Inc appoints Jeff Sacher as interim CFO - marketscreener.com
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer By Investing.com - Investing.com Nigeria
Foghorn Therapeutics appoints Jeff Sacher as interim CFO and treasurer - Investing.com
Why Foghorn Therapeutics Inc. stock remains on buy listsJuly 2025 Price Swings & Reliable Momentum Entry Alerts - Newser
Foghorn Therapeutics (FHTX) names Danforth’s Jeff Sacher interim CFO - Stock Titan
Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target By Investing.com - Investing.com South Africa
Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target - Investing.com India
R/R Acute Myeloid Leukemia Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi - Barchart.com
Published on: 2025-12-02 00:54:46 - Newser
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):